Brain cell reprogramming reverses Alzheimer’s in mice
What if you could replace damaged brain cells with new ones, made from cells already present in the brain? Researchers managed to convert support cells in the brain into new neurons, and mice with Alzheimer’s disease subsequently showed cognitive recovery.
The Alzheimer’s brain gradually loses neurons in regions essential for memory. The body has almost no capacity to replace them. Astrocytes, a type of support cell that is abundant throughout the brain, have long been considered a potential source for new neurons. They are plentiful, widely distributed, and capable of dividing.
The new approach uses a technology the researchers call Nano-ERASER. Via intravenous injection, the system transports antibodies across the blood-brain barrier and into astrocytes. Once inside, the antibodies inhibit a protein called PTBP1, which normally prevents astrocytes from becoming neurons. By blocking this protein, the support cells are reprogrammed into neurons that integrate into existing brain circuits. The study reported that cognitive impairment in the treated mice was reversed.
A clever solution to a persistent problem
One of the major obstacles in brain therapy is the blood-brain barrier, the protective layer between the bloodstream and brain tissue. Most molecules and cells cannot cross it. Nano-ERASER circumvents this problem through a specific antibody transport mechanism. That is technically noteworthy, independent of the Alzheimer’s application.
The method also works in a cell-type-specific way: only astrocytes are targeted, not all brain cells indiscriminately. That level of precision is difficult to achieve with small molecules.
Mice are not people
Mouse models of Alzheimer’s disease are artificial and replicate human Alzheimer’s only partially. Many therapies that work in mice fail to do the same in humans. Even so, the core technology, delivering antibodies to specific brain cell types via the bloodstream, represents a step that may be relevant beyond Alzheimer’s. Clinical studies in humans are the necessary next step.
Search terms to explore further: astrocyte-to-neuron reprogramming, PTBP1 inhibition neurogenesis, blood-brain barrier antibody delivery